Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia

Abers, 2021, An immune-based biomarker signature is associated with mortality in COVID-19 patients, JCI Insight, 6, 10.1172/jci.insight.144455 DiNubile, 2007, Plasma gelsolin: in search of its raison d’être. Focus on “Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin”, Am. J. Physiol.-Cell Physiol., 292, C1240, 10.1152/ajpcell.00007.2007 DiNubile, 2020, Recombinant human plasma gelsolin (rhu-pGSN) improves survival and attenuates lung injury in a murine model of multi-drug resistant Pseudomonas aeruginosa pneumonia, Open Forum Infect. Dis., 7 Finelli, 2021, Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020, JAMA Network Open, 4, e216556, 10.1001/jamanetworkopen.2021.6556 Jain, 2015, Community-acquired pneumonia requiring hospitalization among U.S. adults, N. Engl. J. Med., 373, 415, 10.1056/NEJMoa1500245 Mato, 2020, Outcomes of COVID-19 in patients with CLL: a multicenter international experience, Blood, 136, 1134, 10.1182/blood.2020006965 Messner, 2020, Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection, Cell Syst., 11, 11, 10.1016/j.cels.2020.05.012 Ordija, 2017, Free actin impairs macrophage bacterial defenses via scavenger receptor MARCO interaction with reversal by plasma gelsolin, Am. J. Physiol. Lung Cell. Mol. Physiol., 312, L1018, 10.1152/ajplung.00067.2017 Overmyer, 2021, Large-scale multi-omic analysis of COVID-19 severity, Cell Syst., 12, 23, 10.1016/j.cels.2020.10.003 Piktel, 2010, Recombinant human plasma gelsolin stimulates phagocytosis while diminishing excessive inflammatory responses in mice with Pseudomonas aeruginosa 2epsis, Int. J. Mol. Sci., 21, 2551, 10.3390/ijms21072551 Scarfò, 2020, COVID-19 severity and mortality in patients with chronic lymphocytic leukemia, Leukemia, 34, 2354, 10.1038/s41375-020-0959-x Self, 2018, Low admission plasma gelsolin concentrations identify community-acquired pneumonia patients at high risk for severe outcomes, Clin. Infect. Dis., 69, 1218, 10.1093/cid/ciy1049 Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv preprint accessed April 2021; https://doi.org/10.1101/2021.04.06.21254949. Tannous, 2020, Safety and pharmacokinetics of recombinant human plasma gelsolin in patients hospitalized for nonsevere community-acquired pneumonia, Antimicrob. Agents Chemother., 64, e00579, 10.1128/AAC.00579-20 Yang, 2015, Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function, Am. J. Physiol. Lung Cell. Mol. Physiol., 309, L11, 10.1152/ajplung.00094.2015 Yang, 2019, Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza, F1000Res, 8, 1860, 10.12688/f1000research.21082.1